Antibacterial or Antiviral Activity
|
Lactiplantibacillus plantarum (formerly Lactobacillus plantarum)
|
Spike protein Receptor-binding domain (RBD) |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
Inducible pSIP411 vector |
SARS-CoV-2 vaccine |
[17] |
|
L. plantarum
|
SARS-CoV-2 spike protein(S) |
SARS-CoV-2 |
Expression plasmid pLP-tS |
SARS-CoV-2 vaccine |
[18] |
|
Lactococcus lactis
|
Reuterin |
Limosilactobacillus reuteri (formerly Lactobacillus reuteri)
|
RecT expression vectors; pJP005 andpJP042 |
Antimicrobial activity |
[19] |
|
Lacticaseibacillus casei (formerly Lactobacillus casei)
|
Listeria adhesion protein (LAP) |
Listeria innocua, Listeria monocytogenes
|
Expression vector -pLP401T containing the pAmy promoter |
Mitigation of lethal L. monocytogenes infection |
[20] |
|
L.casei ATCC344
|
Internalins A and B (inlAB) |
L. monocytogenes
|
Expression vector-pLP401-T |
Prevention of L. monocytogenes infection |
[5] |
|
Lacticaseibacillus paracasei (formerly Lactobacillus paracasei)
|
Heavy-chain antibodies (VHHs) |
llama |
Lactobacillus expression vector pLP501 |
Protection against Rotavirus-induced diarrhoea |
[21] |
|
Lc. lactis
|
Alysteserin, CRAMP1 and Laterosporulin |
Synthesised by various bacteria |
PTKR vector, P1 promoter, usp45 gene |
Selective inhibition of Helicobacter pylori
|
[22] |
|
Lactobacillus spp |
Highly pathogenic avian influenza (HPAI) virus protein hemagglutinin 1 (HA1) |
HPAI virus |
E. coli-Lactobacillus shuttle vector pLEM415, lactate dehydrogenase (LDH) promoter, ldhL promoter |
Avian influenza virus vaccine |
[23] |
|
Lactobacillus gasseri NM713 |
Streptococcal M6 protein (CRR6) |
Streptococcus pyogenes
|
Expression plasmid-pSLP111.1 based on the xylose operon promoter |
Oral vaccine against Streptococcus pyogenes
|
[24] |
|
Lactobacillus jensenii
|
HIV-1 entry inhibitor cyanovirin-N |
Cyanobacterium, Nostoc ellipsosporum
|
Expression cassette containing an L. jensenii promoter for the ribosomal protein subunit (PrpsU) |
Antiviral activity |
[25] |
|
Lacticaseibacillus rhamnosus (formerly Lactobacillus rhamnosus)
|
Anti-lectin griffithsin |
Red algae Griffithsia sp. |
NICE system, under PnisA control |
Targets the HIV virus |
[26] |
|
Lc. lactis
|
Glutamate-rich protein (GLURP)-Merozoite surface protein 3 (MSP3) chimeric protein |
Plasmodium falciparum
|
P170 expression system |
Malarial vaccine |
[27] |
Cancer Therapy
|
Lc. lactis
|
KiSS1 |
Human melanoma cell lines |
Expression plasmid pNZ401, nisin inducible promoter |
Cancer therapy for prevention of proliferation and migration of human colon carcinoma HT-29 cells |
[28] |
|
Lc. lactis
|
Human Papilloma Virus 16 E7 protein Ag (LL-E7) and biologically active murine IL-12 |
HPV, murine cells |
Nisin inducible promoter |
Mucosal vaccine for prevention of HPV Type 16-Induced Tumors |
[29] |
|
Lc. lactis
|
Glycosylated tyrosinase related protein-2 |
Murine cells |
Chinese Hamster Ovary-S cell expression system |
Cancer vaccine |
[30] |
|
L. plantarum
|
Oncofetal antigen (OFA) |
Mammalian cancer cells |
pSIP system, inducible PsppA promoter |
Cancer vaccine delivery |
[31] |
|
Lc. lactis
|
Cu/Zn superoxide dismutase |
Human cells |
PTS System, under strong constitutive P32 control |
Defence against carcinogenesis and oxidative damages in the human GIT |
[32] |
Metabolic Activity
|
L. gasseri
|
Glucagon-like peptide (GLP) 1 (1-37) |
Pancreatic β-cell |
SlpA promoter and usp45-LEISS secretion tag |
Treatment of Type 2 diabetes |
[33] |
|
Lc. lactis
|
Glucagon likepeptide-1 |
Pancreatic β-cell |
Plasmid pUB1000 used as expression vector |
Treatment of Type 2 diabetes |
[34] |
|
Lc. lactis NZ9000
|
Osteocalcin |
Murine cell |
PnisA control |
Diabetes and obesity therapy |
[35] |
|
L. reuteri
|
Phenylalanine lyase |
Anabaena variabilis
|
Lactobacillus high production constitutive promoter and ribosome binding sequence from the erythromycin resistance B gene (ermB) |
Treatment of phenylketonuria |
[36] |
|
Lc. lactis
|
Lipase |
Staphylococcus hylicus. |
Nisin inducible promoter |
Treatment of pancreatic insufficiency |
[37] |
Biosensing |
L. reuteri
|
Autoinducer peptide-I (AIP-I) |
Staphylococcus sp |
AgrA-activating promoter P3 for controlled expression of the glucuronidase-expressing gusA reporter gene |
Biosensing AIP-I, a quorum sensing molecule produced by Staphylococcus sp. during pathogenesis. |
[12] |
|
Lc. lactis
|
Enterococcal sex pheromone cCF10 |
Enterococcus faecalis
|
Expression vectors derived from pCF10 |
Biosensing |
[38] |
Immune Modulation |
Lc. lactis
|
Cathelicidin |
Mouse cells |
Nisin induced promoter system |
Reduction of inflammation in mice with colitis |
[28,39] |
|
Lc. lactis
|
Gliadin |
Human cells |
Lc. lactis-specific pT1NX vector (pT1eDQ8d) used for expression, Lactococcal P1 promoter |
Immune stimulation |
[40] |
|
Lc. lactis
|
Myelin peptide fragments |
Human cells |
pIL253 derivative with the ptcB gene promoter, expressing MOG35-55, MBP85-97, PLP139-151 antigens |
Immune stimulation |
[41] |
|
Lc. lactis
|
Interleukin-10 production |
Yersinia pseudotuberculosis
|
Stress-Induced Controlled Expression (SICE) and usp45 promoter |
Trinitrobenzene sulfonic acid (TNBS) induced colitis |
[42] |
|
Lc. lactis
|
Heat-shock protein 65 (Hsp65) |
Mycobacterium leprae
|
Xylose-inducible expression system |
Prevention of atherosclerosis |
[43] |